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7; fax: þ44 191 2BACKGROUND: Extended criteria donor lungs deemed unsuitable for immediate transplantation can be
reconditioned using ex vivo lung perfusion (EVLP). Objective identification of which donor lungs can
be successfully reconditioned and will function well post-operatively has not been established. This
study assessed the predictive value of markers of inflammation and tissue injury in donor lungs
undergoing EVLP as part of the DEVELOP-UK study.
METHODS: Longitudinal samples of perfusate, bronchoalveolar lavage, and tissue from 42 human donor
lungs undergoing clinical EVLP assessments were analyzed for markers of inflammation and tissue
injury. Levels were compared according to EVLP success and post-transplant outcomes. Neutrophil
adhesion to human pulmonary microvascular endothelial cells (HPMECs) conditioned with perfusates
from EVLP assessments was investigated on a microfluidic platform.
RESULTS: The most effective markers to differentiate between in-hospital survival and non-survival
post-transplant were perfusate interleukin (IL)-1β (area under the curve ¼ 1.00, p ¼ 0.002) and
tumor necrosis factor-α (area under the curve ¼ 0.95, p ¼ 0.006) after 30 minutes of EVLP. IL-1β levels
in perfusate correlated with upregulation of intracellular adhesion molecule-1 in donor lung vasculature
(R2 ¼ 0.68, p o 0.001) and to a lesser degree upregulation of intracellular adhesion molecule-1
(R2 ¼ 0.30, p ¼ 0.001) and E-selectin (R2 ¼ 0.29, p ¼ 0.001) in conditioned HPMECs and neutrophil
adhesion to conditioned HPMECs (R2 ¼ 0.33, p o 0.001). Neutralization of IL-1β in
perfusate effectively inhibited neutrophil adhesion to conditioned HPMECs (91% reduction,
p ¼ 0.002).he Authors. Published by Elsevier Inc. on behalf of International Society for Heart and Lung Transplantation. All
rticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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perfusate during EVLP. Blocking the IL-1β pathway during EVLP may reduce endothelial activation
and subsequent neutrophil adhesion on reperfusion; this requires further investigation in vivo.
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(http://creativecommons.org/licenses/by-nc-nd/4.0/).The availability of suitable donor lungs for trans-
plantation falls short of demand and contributes to a
substantial waiting list mortality.1 Ex vivo lung perfusion
(EVLP) is a promising technique to objectively assess and
potentially recondition organs unsuitable for immediate use
and accounts for 20% of transplants in some established
centers.2–5 However, predicting which “higher risk” donor
lungs can be reconditioned effectively and function well
after transplant remains challenging, and the ability to
stratify such organs will increase safe access to lung
transplantation.6 In addition to being an effective donor lung
assessment platform, EVLP could potentially offer an
opportunity to attenuate inflammation and protect vascular
integrity in the lung before implantation.
We have previously demonstrated the feasibility of
identifying pro-inflammatory signals in perfusate during
EVLP of unsuitable donor lungs.7 In this study, we used
samples collected from a large cohort of clinical EVLP
procedures performed as part of the DEVELOP-UK multi-
center trial.8 Our aim was to examine the potential of
markers of inflammation and tissue injury early during
clinical EVLP to distinguish donor lungs that can be
reconditioned and to predict post-transplant outcomes. In
addition, we investigated whether any of these perfusate
markers might have a mechanistic role that would be
amenable to therapeutic modulation on an accessible flow-
based in vitro therapy testing platform for EVLP.
Methods
Study design
This is the prospective mechanistic arm of the DEVELOP-UK trial
(ISRCTN 44922411). Ethics approval was granted, and informed
consent for research was obtained from donor families and lung
transplant recipients (REC 11/NE/0342).8
EVLP protocol
The study included adult donor lungs deemed unsuitable for lung
transplantation by all centers in the United Kingdom but meeting
pre-defined EVLP criteria (Tables S1 and S2 [available in the online
version of this article at www.jhltonline.org]). EVLP assessments
were performed using a Vivoline LS1 EVLP circuit (Vivoline
Medical AB, Lund, Sweden) following 1 of 2 standardized perfusion
protocols previously described in detail.8 Briefly, an initial Hybrid
protocol featured an open left atrium, acellular perfusate, and
perfusate flow limited to 40%–60% of donor calculated cardiac
output (n ¼ 22). Subsequently, the perfusion strategy was changedto a Lund protocol with cellular perfusate (hematocrit 10%–15%)
and full flow perfusion (n ¼ 31). Assessment methods, including
sampling procedures, remained unchanged.
Sample collection
Bronchoalveolar lavage (BAL) was performed in a subsegmental
bronchus of the right or left lower lobes.9 Saline (120 ml)
was instilled via bronchoscopy and suctioned back before start-
ing ventilation at the beginning of EVLP and repeated in the same
lobe but different subsegmental bronchus at the end of perfusion.
Tissue biopsy samples were taken from either the right middle
lobe or the lingula before and after EVLP assessment using a
stapler. These specimens were snap frozen in liquid nitrogen for
protein and RNA isolation and fixed in formaldehyde and paraffin
embedded for immunohistochemistry. A control sample was
collected from the primed EVLP circuit before starting donor lung
perfusion. Repeated perfusate samples (5 ml) were then collected at
15 and 30 minutes after starting perfusion and every 30 minutes
thereafter.
Immunoassays
All protein concentrations measured in perfusate were adjusted to
the donor predicted total lung capacity as an estimate of perfused
donor lung volume and reported as corrected perfusate concen-
trations (pg/ml), as previously described.7 Lactate dehydrogenase
levels were measured in perfusate, BAL, and tissue lysate as per
manufacturer’s instructions (Thermo Fisher Scientific, Rockford, IL).
Perfusate and tissue lysates were analyzed with a V-PLEX Human
Biomarker 40-Plex Kit and a Human MMP 3-Plex Ultra-Sensitive
Kit (both Meso Scale Diagnostics, LLC, Rockville, MD). BAL was
analyzed using a V-PLEX human pro-inflammatory Panel 1 Kit and
a Human MMP 3-Plex Ultra-Sensitive Kit (both Meso Scale
Diagnostics, LLC). Human Syndecan-1 and endothelin-1 were
measured using sandwich enzyme-linked immunosorbent assays
(R&D Systems, Inc., Minneapolis, MN).
Cell culture
Human pulmonary microvascular endothelial cells (HPMECs)
were obtained from PromoCell (Heidelberg, Germany). Peripheral
blood neutrophils were isolated in-house 2 hours before usage from
healthy volunteers through a standard protocol.10
Neutrophil adhesion assay
A microfluidic platform (Cellix Ltd., Dublin, Ireland) was used for
modeling leukocyte adhesion, as previously described.11 Endothe-
lial cell substrates (Vena8; Cellix Ltd.) were pre-coated overnight
Andreasson et al. Role of IL-1b During Clinical EVLP 3with 100 μg/ml fibronectin (Sigma-Aldrich, St Louis, MO) and
HPMECs seeded to a confluent monolayer (1  105 cells/channel).
HPMECs were stimulated with blank perfusate (negative control),
perfusate with 1 ng/ml interleukin (IL)-1β (positive control) (R&D
Systems, Inc.), or clinical EVLP perfusates for 4 hours. For
blocking experiments, perfusates were pre-incubated for 1 hour
with 4 μg/ml anti–IL-1β neutralizing antibody (NAb) (R&D
Systems, Inc.). Primary neutrophils (5  106 cells/ml) were passed
over the HPMEC monolayer at 0.5 dyne/cm2 for 5 minutes. Images
(5 images/channel) were captured in the last 2 minutes, and
average neutrophil adhesion was determined using DucoCell
software (Cellix Ltd.).Flow cytometry
HPMECs conditioned for 4 hours with perfusates were stained with
conjugated antibodies specific for CD31 (WM59), intracellular
adhesion molecule-1 (ICAM-1) (HA58), E-selectin (CL2), and
isotype controls (all eBioscience, San Diego, CA). Samples were
acquired on a FACSCanto II flow cytometer (BD Biosciences,
San Jose, CA) and analyzed with FlowJo software (Tree Star, Inc.,
San Carlos, CA).Immunohistochemistry
Lung tissue taken pre-EVLP and post-EVLP from 4 Declined
lungs (lungs declined from transplantation after EVLP assessment)
and 4 Survival lungs (lungs with recipients surviving to hospital
discharge post-transplant) with highest levels of IL-1β in the
perfusate were examined (n ¼ 16 sections). Immunolocalization of
ICAM-1 (EP1442Y), E-selectin (polyclonal), and neutrophil
elastase (EPR7479) (all Abcam, Inc., Cambridge, MA) was by
the avidin-biotin method with biotinylated secondary antibodies
and subsequent DAB Chromogen staining (Vector Laboratories,
Inc., Burlingame, CA). Five fields (20 magnification) from each
section were scored by 4 blinded arbiters using a semi-quantitative
scoring system (0 ¼ no staining; 1 ¼ weak staining; 2 ¼ moderate
staining; 3 ¼ strong staining).Figure 1 Flow chart of outcome after EVLP in the DEVELOP-UK stu
or lack of consent from donor families. Four donor lungs were excluded,
assessment but were later declined owing to unforeseen logistical reasons
—recipient infected and too unwell when arriving for transplant; (2) ac
unknown left pulmonary artery laceration at procurement, no available
operating room and lack of additional surgical capacity; and (4) accepted
—decline owing to chronic lymphocytic leukemia on donor liver noduleStatistical analysis
A logistic regression approach was used to examine the association
between EVLP success and a number of potential predictors based
on donor characteristics, EVLP protocol, and indices measured
during EVLP using the software package R (R Foundation for
Statistical Computing, Vienna, Austria). Logged protein levels
were analyzed using GraphPad Prism 6 (GraphPad Software Inc.,
La Jolla, CA). The ability of each biomarker to discriminate
between outcome groups (Survival, Non-survival, and Decline)
was assessed with Mann-Whitney U test and a receiver operating
characteristics (ROC) curve with calculation of the area under the
curve (AUC) followed by Benjamini-Hochberg false discovery rate
controlling procedure at p-value o 0.05.12 In vitro experiments
were analyzed with paired or unpaired t-tests and goodness of fit by
linear regression.
Results
Between April 2012 and July 2014, 53 donor lungs deemed
unsuitable for immediate transplantation by UK lung
transplant programs were evaluated with EVLP in the
DEVELOP-UK study. A detailed description of the study
population can be found in the final study report.8
Study group
Samples were available from 42 of 53 donor lungs forming
the study group. There were 11 donor lungs with incomplete
sampling excluded from this study (Figure 1). From the 42
donor lungs included, 16 (38%) were transplanted, and 26
did not satisfy criteria for transplant after EVLP.
The results were compared between 3 subgroups depend-
ing on outcome: transplanted lungs with recipient survival to
hospital discharge (Survival, n ¼ 11), transplanted lungs
with recipient in-hospital mortality before discharge (Non-
survival, n ¼ 5), and donor lungs declined from trans-
plantation after EVLP (Declined, n ¼ 26). There was nody. *Seven assessments lacked samples owing to either early cases
as they were accepted for transplantation on the basis of the EVLP
not related to lung performance, as follows: (1) accepted lung pair
cepted lung pair—successful selective right lung perfusion owing
single lung recipient; (3) accepted left single lung—emergency in
lung pair successfully preserved on EVLP while awaiting histology
histology.
Table 1 Univariate Logistic Regression Analysis of Predictors of Successful EVLP Reconditioning (EVLP Success)
Variable Category or units Number Number of successes OR (95% CI)
EVLP protocol Lund 31 14 1
Hybrid 22 8 0.69 (0.23, 2.13)
Donor age Based on a 10-year increase 53 22 1.47 (0.89, 2.44)
Sex (reference: male) Female 26 9 0.57 (0.19, 1.72)
Male 27 13 1
Smoking (reference: non-smoker) Non-smoker 29 13 1
Smoker 24 9 0.74 (0.25, 2.23)
Ischemic time Based on 1-hour increase 48a 21 1.00 (0.61, 1.64)
Duration of ventilation Based on 1-day increase 53 22 1.18 (0.86, 1.60)
Optimized donor PaO2/FIO2 ratio before EVLP Based on 100-mm Hg increase 53 22 0.80 (0.50, 1.28)
Donor type (reference: DBD) DBD 39 17 1
DCD 14 5 0.72 (0.20, 2.54)
PaO2/FIO2 ratio after EVLP Based on 100-mm-Hg increase 48
a 22 1.35 (0.85, 2.13)
Compliance start Based on 10-ml/mbar increase 28a 15 1.26 (0.93, 1.71)
Change in complianceb Based on 10-ml/mbar increase 15a 7 0.98 (0.52, 1.86)
Airway resistance start Based on 1-mbar/liter/sec increase 24a 11 0.93 (0.78, 1.10)
Change in airway resistanceb Based on 1-mbar/liter/sec increase 12a 4 2.28 (0.44, 11.77)
Peak airway pressure start Based on 1-cm H2O increase 41
a 18 0.88 (0.74, 1.04)
Change in peak airway pressureb Based on a 1-cm H2O increase 24
a 9 1.06 (0.85, 1.32)
EVLP time Based on 1-hour increase 49a 20 0.95 (0.54, 1.65)
CI, confidence interval; DBD, donation after brain death; DCD, donation after circulatory death; EVLP, ex vivo lung perfusion; OR, odds ratio; PaO2/FIO2,
arterial oxygen partial pressure/fraction of inspired oxygen.
A logistic regression analysis was used to examine the association between successful reconditioning and a number of potential predictors based on donor
characteristics and indices measured during EVLP. ORs are presented for different categories or, in the case of continuous variables, based on a unit
increase in the variable. Although some of the point estimates for ORs varied from 1, the associated 95% CI included 1 in all instances.
aExcluding patients with missing data.
bChanges defined as start  end.
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organ assessment indices independently influenced EVLP
outcome, including perfusion protocol (Table 1). The
median time of EVLP was 175 minutes (range, 73–383
minutes) with no significant difference between the 3 out-
come subgroups. Detailed donor and recipient character-
istics are summarized in Table S3 (available in the online
version of this article at www.jhltonline.org). Details of
perioperative and post-transplant outcomes are listed in
Table 2. There was a trend toward worse early allograft
function (primary graft dysfunction [PGD] severity, need for
extracorporeal mechanical oxygenation, time of invasive
ventilation, and intensive care stay) in the Non-survival
group compared with recipients in the Survival group.
Figure 2 shows PGD scores by outcome group and time
post-transplant. There was an increased rate of early PGD
grade 3 in the Non-survival group (60% PGD grade 3 in
Non-survival group compared with 27% PGD grade 3 in
Survival group at 48 hours).
Biomarker analysis
Bronchoalveolar lavage
No significant differences in markers of inflammation or
tissue injury were found in BAL samples when comparing
samples from pre-EVLP and post-EVLP. Similarly, BAL
levels of analyzed markers did not differ significantly
between outcome groups pre-EVLP or post-EVLP.Donor lung tissue
In lung tissue lysates, the levels of a large number of
inflammatory markers (IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6,
IL-8, IL-10, IL-12p70, IL-13, interferon-γ, monocyte
chemotactic protein-1, macrophage inflammatory protein-
1α, tumor necrosis factor [TNF]-α, and TNF-β) increased
significantly between the start and end of perfusion.
However, none of the proteins measured in tissue differed
significantly between the individual outcome groups.
Perfusate
In perfusate, 40 of 45 markers were detectable and increased
significantly in serial measurements during EVLP. Only
matrix metalloproteinase-9, placental growth factor (PlGF)
PIGF, TNF-β, serum amyloid A, and vascular endothelial
growth factor A remained unchanged over the course of
perfusion. No marker was significantly different between
outcome groups at the 15-minute sampling time point, but at
30 minutes of EVLP, differences were established between
groups in 2 biomarkers. These separations were maintained
but were not increased at later time points.
The protein markers with ability to differentiate Declined
lungs from Survival lungs were IL-1β and TNF-α in
perfusate after 30 minutes of perfusion (Mann-Whitney U ¼
58.8, Z ¼ 2.81, p ¼ 0.004 and Mann-Whitney U ¼ 49.5,
Z ¼ 3.11, p ¼ 0.001, respectively) (Figure 3B and F). The
AUC for ROC curve of 30 minutes perfusate levels for
Table 2 Recipient Post–Lung Transplant Outcomes in EVLP Arm
EVLP
number
Age
(years)/sex Diagnosis
High
risk Tx CPB
PaO2/FIO2 ratio at
24 hours post-Tx
(mm Hg)
PGD score
at
72 hours
Post-operative
ECMO
Invasive
ventilation,
days
ICU stay
(days)
Hospital stay
(days)
Survival to
discharge
1-year
survival
Cause of
death
27 59/M IPF No Yes—DL Yes 378 0 No 2 3.5 46 Yes Yes
28 32/F CF NIV Yes—DL No 217 3 No 1.5 7.5 21 Yes Yes
29 56/M COPD NIV Yes—DL Yes 335 1 Yes 15 15 25 Yes No Pneumonia
30 62/F IPF NIV Yes—SL Yes 428 (ECMO) 3 Yes 65 65.5 93 Yes Yes
31 44/M PAH PAH Yes—DL Yes 221 3 Yes 0.33 21 44 Yes Yes
32 48/M IPF RV↓ Yes—DL Yes 286 1 No 0.5 1.5 16 Yes Yes
33 49/M IPF No Yes—DL Yes 326 (ECMO) 2 Yes 70 68 87 Yes Yes
34 59/F COPD No Yes—DL Yes 146 1 No 1.5 5 25 Yes Yes
35 64/M COPD NIV Yes—DL No 278 2 No 0.5 2.5 16 Yes Yes
36 20/M CF NIV Yes—DL Yes 203 2 No 2.5 6.5 17 Yes Yes
37 60/M COPD No Yes—DL Yes 345 1 No 1.5 5.5 25 Yes Yes
38 56/M IPF No Yes—DL Yes 113 (ECMO) 3 Yes 100a 98 100a No No PGDb and sepsis
39 56/F BE No Yes—DL Yes 257 1 No 3 14 31a No No Pneumonia and sepsis
40 56F COPD No Yes—DL Yes 401 2 No 18a 18a 18a No No PGDb and hypoxic brain
injury
41 23/M CF NIV þ
RV↓
Yes—DL Yes 368 (ECMO) 1 Yes 3 15 63a No No PGDb and pneumonia
42 58/M IPF NIV Yes—SL Yes 71 3 No 31a 31a 31a No No PGDb and respiratory
arrest
BE, bronchiectasis; CF, cystic fibrosis; COPD, chronic obstructive pulmonary disease; CPB, cardiopulmonary bypass; DL, double-lung; ECMO, extracorporeal membrane oxygenation; EVLP, ex vivo lung perfusion;
F, female; ICU, intensive care unit; IPF, idiopathic pulmonary fibrosis; M, male; NIV, non-invasive ventilation; PAH, pulmonary artery hypertension; PaO2/FIO2, arterial oxygen partial pressure/fraction of inspired oxygen;
PGD, primary graft dysfunction; RV↓, right ventricular failure; SL, single-lung; Tx, transplantation.
aDeath before hospital discharge.
bOf 4 recipients in whom we believe PGD played a role in the cause of death, 2 had severe PGD at all time points up to 72 hours. One patient had very severe graft failure on arrival in the ICU and had to be salvaged with
emergency ECMO. ECMO was weaned just before 72 hours and the patient had at this time point a saturation reflecting mild PGD, even though he never recovered and continued to need hospital treatment for failing graft
function until his death at 63 days post-Tx. The fourth recipient had moderately severe PGD up to 72 hours, which never recovered. The patient was never weaned off invasive ventilation and died 18 days post-transplant.
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Figure 2 PGD score by outcome subgroup and time post-
transplant. PGD is the clinical syndrome of chest radiographic
changes and poor oxygenation that represents early acute injury to
the transplanted lung. The PGD scores used in the study were as
defined in the International Society for Heart and Lung
Transplantation consensus definition.28 The distribution of the
PGD score by study group, measured at baseline and 24, 48, and
72 hours after the transplant, is shown. A score of 0 represents no
evidence of PGD, and a score of 3 represents the most severe form
of PGD.
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0.83 (p ¼ 0.002) for TNF-α (Figure 3C and G). The most
effective markers to differentiate recipient in-hospital
mortality (Non-survival group) from mortality after suc-
cessful discharge (Survival group) were similarly perfusate
IL-1β (Mann-Whitney U ¼ 0.0, Z ¼ 3.12, po 0.001) and
TNF-α (Mann-Whitney U ¼ 3.0, Z ¼ 2.78, p ¼ 0.003)
after 30 minutes of perfusion (Figure 3B and F). ROC curve
analysis showed high precision for both IL-1β (AUC ¼
1.00, p ¼ 0.002) and TNF-α (AUC ¼ 0.95, p ¼ 0.006) to
differentiate between the Non-survival and Survival groups.
With a total lung capacity scaled cutoff value of 0.1 pg/ml,
perfusate IL-1β after 30 minutes of EVLP had a sensitivity
and specificity of 100% to diagnose Non-survival lungs.
The predictive value of perfusate IL-1β and TNF-α after
30 minutes of EVLP remained robust when applied to the
primary study end-point of 1-year post-transplant survival;
the AUC for ROC curve of 1-year Non-survival vs Survival
was 0.93 (p ¼ 0.005) for IL-1β and 0.95 (p ¼ 0.003) for
TNF-α (Figure S3 [available in the online version of this
article at www.jhltonline.org]). With a total lung capacity
scaled cutoff value of 0.1 pg/ml, perfusate IL-1β after
30 minutes of EVLP had a diagnostic sensitivity of 83% and
specificity of 100% for recipient 1-year post-transplant
mortality.
Subanalysis with adjustment for EVLP protocol showed
no significant impact on protein levels. Detailed protein
levels and fold changes during EVLP in the 3 lung
compartments are illustrated in Figures S1 and S2 (available
in the online version of this article at www.jhltonline.org).
Molecular and cellular staining in EVLP donor
lung tissue
ICAM-1 staining intensity was elevated in the Declined
group post-EVLP (mean 2.85, SEM 0.20) compared withpre-EVLP (mean 1.79, SEM 0.42; t3 ¼ 4.67, p ¼ 0.019) and
with post-EVLP in the Survival group (mean 1.65, SEM
0.37; t6 ¼ 2.85, p ¼ 0.029) (Figure 4B). Endothelial ICAM-
1 expression in lung tissue was strongly correlated with
perfusate levels of IL-1β from the same lung (R2 ¼ 0.68,
p o 0.001) (Figure 4C). E-selectin staining followed a
similar trend but was not significantly different between
groups, and the correlation with perfusate IL-1β levels was
weaker (R2 ¼ 0.25, p o 0.047). Survival lungs contained
significantly fewer neutrophils after EVLP (mean 7.0, SEM
2.04) compared with Declined lungs (mean 22.8, SEM 2.90;
t6 ¼ 4.44, p ¼ 0.004). EVLP reduced the numbers of
neutrophils in both Survival and Declined lungs but not
significantly (data not shown).
Neutrophil adhesion assay
Adhesion of primary human neutrophils to a monolayer of
HPMECs conditioned with perfusate samples from 16
individual clinical EVLP assessments, including Survival
(n ¼ 7) and Declined (n ¼ 9) lungs, was quantified using a
flow-based in vitro platform with 3 neutrophil donor repeats.
Neutrophil adhesion to HPMECs conditioned with perfusate
from the beginning of EVLP was similar between Survival
and Declined groups but significantly higher in the group of
HPMECs conditioned with end of EVLP perfusate from
Declined lungs (mean 10.3, SEM 4.5) compared with
Survival lungs (mean 2.5, SEM 0.9; t92 ¼ 2.10, p ¼ 0.038)
(Figure 5A). Neutrophil adhesion to conditioned endothe-
lium was positively correlated with perfusate IL-1β levels
(R2 ¼ 0.33, p o 0.001) (Figure 5B).
Adhesion molecule expression
HPMECs conditioned with perfusate from end of EVLP of
Declined donor lungs showed significantly elevated
E-selectin and ICAM-1 expression compared with perfusate
from Survival lungs (ICAM-1: meanDeclined 27.9, SEM
1.9 vs meanSurvival 19.4, SEM 1.7; t22 ¼ 3.31, p ¼ 0.003;
E-selectin: meanDeclined 8.8, SEM 1.3 vs meanSurvival 5.3,
SEM 0.8; t22 ¼ 2.21, p ¼ 0.038) (Figure 6A and B). IL-1β
levels in perfusate were positively correlated with expres-
sion of ICAM-1 (R2 ¼ 0.30, p ¼ 0.001) and E-selectin
(R2 ¼ 0.29, p ¼ 0.001) (Figure 6C and D).
Inhibition of neutrophil adhesion
Pre-treatment of perfusates with an anti–IL-1β NAb before
HPMEC conditioning effectively reduced neutrophil adhe-
sion (n ¼ 5 neutrophil donor repeats) induced by perfusate
from a highly inflamed Declined lung (IL-1β 592 pg/ml)
(mean 168.1, SEM 51.7 vs meanNAb 10.5, SEM 7.8; t4 ¼
4.64, p ¼ 0.009) and from a transplanted Non-survival lung
with PGD and early in-hospital mortality (IL-1β 49 pg/ml)
(mean 18.0, SEM 1.9 vs meanNAb 6.4, SEM 1.3; t4 ¼ 4.12,
p ¼ 0.015) (Figure 7A). A similar pattern of reduced ICAM-1
and E-selectin expressions was seen when perfusates from
4 representative Declined EVLP lungs and 4 representative
Figure 3 (A–H) Perfusate biomarkers after 30 minutes of EVLP—association with EVLP performance and recipient in-hospital
mortality. Perfusate levels of IL-1β (A) and TNF-α (E) over the course of the EVLP assessment separated into 3 outcome groups (mean 
SEM): Survival, Non-survival, and Declined. Box and whisker plots show perfusate levels of IL-1β (B) and TNF-α (F) for the respective
groups at the 30-minute sampling time point with a total lung capacity adjusted cutoff at 0.1 pg/ml (dotted line). ROC curves for potential of
IL-1β (C) and TNF-α (G) as biomarkers of EVLP performance (Survival vs Declined groups) in perfusate at 30 minutes of EVLP. (D) and
(H) show ROC curves for the potential of perfusate IL-1β and TNF-α as biomarkers of in-hospital post-transplant mortality (Survival vs Non-
survival groups) at the 30-minute sampling time point. As early as 30 minutes into the EVLP assessment, both cytokines were efficiently
discriminatory between the 3 groups in samples from the circulating perfusate fluid. **p o 0.01, ***p o 0.001.
Andreasson et al. Role of IL-1b During Clinical EVLP 7Non-survival EVLP lungs were pre-treated with anti–IL-1β
NAb. A 32% reduction of ICAM-1 (mean 22.2, SEM 3.5 vs
meanNAb 15.0, SEM 2.2; t7 ¼ 2.67, p ¼ 0.032) and 57%
reduction of E-selectin expression (mean 7.5, SEM 2.3 vs
meanNAb 3.2, SEM 0.9; t7 ¼ 5.25, p ¼ 0.001) was observed
on treated cells (Figure 7B and C).
Discussion
In this study, we demonstrate that an early pro-inflammatory
signal in perfusate during clinical EVLP of extended criteria
donor lungs predicts the likelihood of successful EVLP
as well as early and mid-term post-transplant outcomes.Donor lungs are highly susceptible to injury in the critical
care environment, and the extent of injury is difficult to
assess at the time of organ procurement, making current
donor lung acceptance criteria poor discriminators of lung
injury.13–16 Correspondingly, we found no evidence that
specific donor characteristics or physiologic parameters
independently influenced the EVLP outcome in this cohort.
However, post-transplant non-surviving recipients exhibited
inferior allograft function (shown as higher rates of severe
PGD, need for extracorporeal mechanical oxygenation, and
need for long-term invasive ventilation), which contributed
to the very high incidence of adverse outcomes among
EVLP lung recipients in this study. We demonstrated a
Figure 4 (A–E) Expressions of ICAM-1 and E-selectin in immunohistochemistry (IHC) stained clinical EVLP donor lung tissue and
association with perfusate IL-1β levels. (A) Paraffin-embedded donor lung sections DAB stained for ICAM-1 expression. Arrows mark the
low-intensity stained (i) or high-intensity stained (ii) pulmonary vascular endothelium. Unselective background staining seen on adhesive
alveolar epithelium. Box and whisker plots show average ICAM-1 (B) and E-selectin (D) staining intensity scores for pre-EVLP and post-
EVLP biopsy specimens from 4 Declined lungs and 4 Survival lungs. Scatter plots show the correlation between average ICAM-1 (C) and
E-selectin (E) intensity scores in the same experiment and corresponding perfusate IL-1β levels (linear regression line with 95% confidence
intervals). *p o 0.05, ***p o 0.001.
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minutes in declined donor lungs compared with transplanted
lungs. Furthermore, we found clear differences in donor
lungs transplanted with good outcome—survival to hospital
discharge and 1-year survival—compared with lungs trans-
planted with early recipient mortality, hence providing
unique information that standard criteria did not. Perfusate
levels of IL-1β measured 30 minutes into EVLP could
distinguish subsequent in-hospital mortality with asensitivity and specificity of 100% and 1-year survival with
similar precision. BAL appears to show a comparable but
weaker signal than seen in perfusate. With bronchoscopy
being more invasive and the quality of BAL more user
dependent than perfusate sampling, the benefit of perform-
ing BAL for biomarker identification during EVLP is
questionable.
Acute donor lung injury is characterized by
acute inflammation, increased vascular permeability, and
Figure 6 (A–D) Expression of cell surface adhesion molecules on conditioned HPMECs and association with perfusate IL-1β levels.
Flow cytometry investigation of ICAM-1 (A) and E-selectin (C) expression on conditioned HPMECs compared between cells stimulated
with start or end EVLP perfusates from 7 Survival lungs and 9 Declined lungs (mean SEM). Scatter plots show the association between the
fraction of conditioned endothelial cells positive for ICAM-1 (B) and E-selectin (D) in the same experiment and corresponding perfusate
IL-1β levels (linear regression line with dotted 95% confidence intervals). Endothelial adhesion molecule expressions were significantly
higher on cells conditioned with end perfusates from Declined lungs compared with start perfusates from the same lungs (only ICAM-1) and
end perfusates from Survival lungs. ICAM-1 and E-selectin expressions were positively correlated to IL-1β levels in the perfusate used to
condition the endothelial cells. *p o 0.05, **p o 0.01.
Figure 5 Neutrophil adhesion to conditioned human pulmonary microvascular endothelial cells and association with perfusate IL-1β
levels. (A) In vitro neutrophil adhesion comparison between HPMECs conditioned with start or end EVLP perfusates from 7 Survival lungs
and 9 Declined lungs (n ¼ 3 neutrophil donor repeats with each donor lung perfusate sample; mean  SEM). (B) Correlation between
average neutrophil adhesions in the same experiment and corresponding perfusate IL-1β levels (n ¼ 3 neutrophil donor repeats with each
donor lung perfusate sample; linear regression line with dotted 95% confidence intervals). The neutrophil adhesion was significantly higher to
cells conditioned with end perfusates from Declined lungs compared with start perfusates from the same lungs and end perfusates
from Survival lungs. Neutrophil adhesion was positively correlated to IL-1β levels in the perfusate used to condition the endothelial cells.
*p o 0.05, ***p o 0.001.
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Figure 7 Effect of blocking perfusate IL-1β with an anti–IL-1β
neutralizing antibody. In vitro effect of anti–IL-1β NAb pre-
treatment on neutrophil adhesion (A) to HPMECs conditioned with
perfusate from either a Declined lung or a Non-survival lung
(n ¼ 5 neutrophil donor repeats; mean  SEM). Effect of IL-1β
NAb pre-treatment on ICAM-1 (B) and E-selectin (C) expressions
on HPMECs conditioned with perfusate from either Declined lungs
or Non-survival lungs (n ¼ 4 donor lung perfusates from each
group). Pre-treatment of perfusates with an IL-1β NAb efficiently
reduced neutrophil adhesion and adhesion molecule expressions on
conditioned pulmonary endothelial cells in vitro. *p o 0.05,
**p o 0.01, ****p o 0.0001.
The Journal of Heart and Lung Transplantation, Vol ], No ], Month ]]]]10neutrophil infiltration.17,18 Therefore, we assessed the effect
of the perfusate milieu from clinical EVLP runs on
neutrophil–endothelial cell interactions in an in vitro model.
We found perfusate IL-1β to be the most potent activator of
pulmonary endothelium with concentrations strongly corre-
lated with neutrophil adhesion and adhesion molecule
expressions in lung tissue, which supports previous studies
outside EVLP linking IL-1β with acute lung injury and
ischemia-reperfusion injury.19–22 An activated endothelium
during EVLP will promote recipient neutrophil adherence
on reperfusion and may explain the increased rate of PGD
seen in the Non-survival group. A similar picture and
correlation to perfusate IL-1β levels was seen on condi-
tioned endothelial cells in vitro where both neutrophil
adhesion and adhesion molecule expressions could be
significantly reduced by specifically blocking IL-1β in the
perfusate. The therapeutic potential of IL-1β neutralizationduring clinical EVLP of extended criteria donor lungs has
not been examined and warrants further investigation.
Our findings support recent observations made by
Machuca et al23 demonstrating the feasibility of detecting
perfusate biomarkers during clinical EVLP that might
improve donor lung assessment. IL-8, proposed as one of
the optimum markers of EVLP transplant outcome in their
study, has consistently shown potential in previous studies
of donor lung injury from our group.24–26 The potential of
IL-8 to discriminate successful EVLP in our pilot study was
enhanced by combining IL-8 with IL-1β. In this cohort,
perfusate IL-8 levels were higher in Declined lungs
compared with transplanted lungs but could not significantly
differentiate between groups. As perfusate IL-1β was a
marker on its own, the combination with IL-8 did not add
any significant value. Similar to findings in our single-center
pilot study, there was a trend toward an association between
levels of several pro-inflammatory markers in perfusate and
BAL and allograft function (PaO2/FIO2 ratio at 72 hours and
lung function tests at follow-up), but none reached statistical
significance.
The role of the endothelin-1 pathway as a biomarker
for donor lung assessment during EVLP described by
Machuca et al27 could not be replicated in our study.
Perfusate endothelin-1 levels were similar in all groups,
whether assessing survival, PGD, or need for extracorporeal
mechanical oxygenation post-transplant.
A limitation of our study is its relative sample size with
42 human EVLP assessments included, yet this number is
one of the largest cohorts reported to date and sufficient to
demonstrate the feasibility of using perfusate markers to
classify successful EVLP. All 42 donor lungs in this study
were assessed with EVLP with intent for transplantation
following pre-defined criteria for transplant suitability to
reduce center bias in decision making. All protein analyses
on collected samples were performed after completion of the
EVLP procedure and had no impact on decisions at the time.
Future studies will need to investigate emerging real-time
cytokine tests, as time-sensitive assays with high sensitivity
will be essential for the utility of any biomarker during
clinical EVLP.
In conclusion, the results of this study validate our
previous findings in a pilot study and clearly demonstrate
the potential role of IL-1β as a biomarker of EVLP
reconditioning and, more importantly, post-transplant sur-
vival. Therapeutic targeting of IL-1β provides an exciting
opportunity to decrease endothelial activation and poten-
tially reduce the incidence of early graft injury post-
transplant. If successful, these principles may expand to
other organs with ischemia-reperfusion injury.Disclosure statement
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